Dhirendra K. Simanshu

Leidos (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index5.9kcitations174works4.82yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(47), Enzyme Structure and Function(34), Cancer, Hypoxia, and Metabolism(23), Lipid Membrane Structure and Behavior(16), Receptor Mechanisms and Signaling(15)

Publications174 total

Supplementary Data from Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity

2025Open Access

Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

Molecular Cancer Therapeutics·2025

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Molecular Cancer Therapeutics·2025

Structural basis for LZTR1 recognition of RAS GTPases for degradation

5 cited

Science·2025· 5 cited

Molecular glues that facilitate RAS binding to PI3Kα promote glucose uptake without insulin

7 cited

Science·2025· 7 cited

Abstract PS7-04: BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia

1 cited

Clinical Cancer Research·2025· 1 cited

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

13 cited

Science·2025· 13 cited

Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints

6 cited

Journal of Biological Chemistry·2025· 6 citedOpen Access

Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine

3 cited

Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access

Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models

Cancer Research·2025

Abstract 4378: BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models

4 cited

Cancer Research·2025· 4 cited

Supplementary Figure S6 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Table S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S3 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Table S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S5 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Material and Methods from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

page 1 of 9Next →

Frequent Co-authors

Frank McCormick(21), Dwight V. Nissley(19), Dinshaw J. Patel(17), Dominic Esposito(17), Timothy H. Tran(13), Andrew G. Stephen(13), Srisathiyanarayanan Dharmaiah(11), Simon Messing(10), Lucy Malinina(8), Rhoderick E. Brown(8), Julian G. Molotkovsky(7), Albert H. Chan(6), Troy Taylor(6), Thomas J. Turbyville(6), Chris Neale(5), Ravi Kanth Kamlekar(5), Felice C. Lightstone(5), Patrick Alexander(5), M.R.N. Murthy(5), Xiuhong Zhai(4)